Janus kinase 2–Signal transducer and activator of transcription signaling pathway (JAK2–STAT)

The Janus kinase 2–Signal transducer and activator of transcription (JAK2–STAT) signaling pathway is a critical intracellular cascade that mediates responses to various cytokines and growth factors, particularly those involved in hematopoiesis and immune regulation (StatPearls, 2023). Upon ligand binding to cell surface receptors, JAK2 is activated and phosphorylates the receptor, creating docking sites for STAT proteins, which are then phosphorylated, dimerize, and translocate to the nucleus to regulate gene expression (Nature Reviews Cancer, 2009). Dysregulation of this pathway, often through the JAK2 V617F mutation, is a hallmark of myeloproliferative neoplasms (MPNs) such as polycythemia vera and myelofibrosis, leading to uncontrolled cell growth (NEJM, 2005). Therapeutic intervention primarily focuses on small-molecule JAK inhibitors, such as ruxolitinib and fedratinib, which compete for the ATP-binding site of the JAK2 kinase domain to suppress overactive signaling (Blood, 2011). While effective in reducing splenomegaly and constitutional symptoms in MPN patients, these drugs can cause significant hematologic toxicities, including anemia and thrombocytopenia, due to the pathway's essential role in normal blood cell production (Lancet Oncology, 2012).

Other names

JAK-STAT signaling pathwayJAK2/STAT pathwayJanus kinase 2/Signal transducer and activator of transcription pathway

Inhibition of the Janus kinase 2 (JAK2) enzyme, which prevents the phosphorylation and activation of Signal Transducer and Activator of Transcription (STAT) proteins, thereby blocking the transcription of genes involved in cell proliferation and survival.